CYRI-B-mediated macropinocytosis drives metastasis via lysophosphatidic acid receptor uptake

• DOI: 10.7554/elife.83712
• Publication Date: 2024-05-07T11:25:07Z
• Authors: Savvas Nikolaou; Amelie Juin; Jamie A Whitelaw; Nikki R Paul; Loic Fort; Colin Nixon; Heather J Spence; Sheila Bryson; Laura M Machesky
• Keywords: 0301 basic medicine; actin cytoskeleton; macropinocytosis; QH301-705.5; Science; pancreatic cancer; Proto-Oncogene Proteins p21(ras); Mice; 03 medical and health sciences; Cell Line, Tumor; cell biology; endocytosis; metastasis; Animals; Humans; chemotaxis; Biology (General); Receptors, Lysophosphatidic Acid; Neoplasm Metastasis; mouse; cancer biology; Cancer Biology; Cell Proliferation; Q; R; 3. Good health; Pancreatic Neoplasms; Disease Models, Animal; Medicine; Pinocytosis; Carcinoma, Pancreatic Ductal

Pancreatic ductal adenocarcinoma carries a dismal prognosis, with high rates of metastasis and few treatment options. Hyperactivation of KRAS in almost all tumours drives RAC1 activation, conferring enhanced migratory and proliferative capacity as well as macropinocytosis. Macropinocytosis is well understood as a nutrient scavenging mechanism, but little is known about its functions in trafficking of signalling receptors. We find that CYRI-B is highly expressed in pancreatic tumours in a mouse model of KRAS and p53-driven pancreatic cancer. Deletion of Cyrib (the gene encoding CYRI-B protein) accelerates tumourigenesis, leading to enhanced ERK and JNK-induced proliferation in precancerous lesions, indicating a potential role as a buffer of RAC1 hyperactivation in early stages. However, as disease progresses, loss of CYRI-B inhibits metastasis. CYRI-B depleted tumour cells show reduced chemotactic responses to lysophosphatidic acid, a major driver of tumour spread, due to impaired macropinocytic uptake of the lysophosphatidic acid receptor 1. Overall, we implicate CYRI-B as a mediator of growth and signalling in pancreatic cancer, providing new insights into pathways controlling metastasis.